No One Owns the Cure
Executive SummaryThis month, as Canada co-hosts the FIFA World Cup — welcoming hundreds of thousands of visitors to stadiums and fan festivals in Toronto and Vancouver1 — it does so as a country that has, for the first time since 1998, lost its measles-free status.2 A World Cup works because everyone in the stadium agrees on the rules, the score is visible to all, and a referee has the authority to enforce both. Canada’s immunization system has none of those three things: the rules vary by province, the scoreboard is dark in ten of thirteen jurisdictions, and no single body has the authority to call the game. Mass gatherings, imported cases, an unprepared system — the tournament is an unusually public test of a quieter failure.
Trust did not so much collapse as relocate. Canadians still report high confidence in their family doctors and pharmacists, even as roughly a quarter say they have declined a vaccine a physician recommended.5 The most credible voices in the system are no longer the ones who set strategy or control supply. Rebuilding confidence therefore depends on actors who do not answer to one another: manufacturers, federal and provincial public-health bodies, regulators, clinicians, pharmacists, hospitals, schools, community and Indigenous health leaders, and the platforms where the argument is actually waged — each controlling a single lever and dependent on the others.
Each holds one lever; none can reach the rest.
Two things are true at once, and the response usually addresses only the first. There is a demand problem with deep roots — a hardened, politically sorted reluctance shaped by grievance, identity, and the memory of a health decision turned into a political ultimatum. It will not yield to a better fact sheet, and no facilitator can argue a person out of it. There is also a coordination problem: the actors who could respond — manufacturers, federal and provincial agencies, regulators, clinicians, pharmacists, hospitals, schools, community and Indigenous health leaders, and the platforms where the argument is waged — each hold one lever, and none can reach the rest. This paper is candid about the first problem and focused on the second. The demand problem is not one a workshop solves by changing minds; the coordination problem is precisely the kind a structured process can. It maps that challenge across three composite vantage points — a vaccine manufacturer, a public-health agency, and a front-line delivery system — and describes the process that converts shared concern into an owned plan before a season’s window closes.
The Crisis Is Measurable, and the Harm Has Arrived.
The numbers describe a system that understands its problem and has not yet been able to act on it together. An outbreak that began in late 2024 spread across several provinces through 2025, concentrated among unvaccinated children, and cost the country a status it had held for a quarter of a century.2,3 Two-dose vaccination among seven-year-olds had slipped from 85 percent to 75 percent in four years — below the roughly 95 percent line epidemiologists treat as the floor for measles control.4 None of this reflects an absence of knowledge about what protects a population. It reflects how many separate hands must move for that knowledge to reach an arm.
A case count is the abstraction. The cost is what the count is made of. The outbreak fell almost entirely on the unprotected — roughly seven in eight of those infected were unvaccinated — and it concentrated where coverage had slipped furthest, with the large majority of 2025 cases in just two provinces.18 The human toll is the part that does not appear in a coverage table: infants have died, and a disease most Canadians had filed under “solved” has fallen hardest on newborns and pregnant patients, who have borne a disproportionate share of the most severe illness.19 These are not statistical artefacts of a busy season; they are the predictable arrival of a preventable disease in a population that had stopped being protected against it.
The cost is also measurable in a second currency: hospital beds. When prevention slips, the consequences land downstream, on the emergency departments and wards least able to influence the demand that produced them — and not from measles alone, but across the whole family of vaccine-preventable respiratory disease.6
Set the two numbers beside each other and the economics are almost absurd. A publicly funded dose is priced in the tens of dollars; a single severe hospitalization runs to tens of thousands. Prevention is not merely the humane choice — it is the cheaper one by nearly three orders of magnitude, which is precisely why a coordination failure that lets uptake slip is so expensive a way to save money.
If the cost is this clear and the math this lopsided, the obvious question is why the system cannot simply act on it. Part of the answer is that, in much of the country, the system cannot even see the problem clearly enough to act. Whether a province can tell the public how protected its children are turns out to vary as much as the coverage itself.
A country that cannot see its own coverage in ten of thirteen jurisdictions is a country fighting an outbreak partly blindfolded — and it is doing so while a far larger weather system moves across the border above it.
The pressure is regional, but the weather system is continental.
Over 2025 and into 2026 a series of United States federal decisions reshaped the vaccine landscape: the national immunization advisory committee was replaced, roughly half a billion dollars in mRNA research was cancelled, COVID-19 vaccines were removed from the routine schedule for healthy children and pregnant people, and eligibility for updated shots was narrowed.12,13 These choices are American, but they travel north through shared platforms and organized networks that coordinate across the border more fluently than the public-health response coordinates within either country.14
So the cost is plain — in lives, in suffering, and in beds — the math favours prevention overwhelmingly, the data to act is at least partly available, and the pressure is intensifying from both inside and outside the country. A problem this legible ought to be a problem already being solved. That it is not points to a misdiagnosis: the system has been treating the wrong disease.
The Wrong Disease Is Being Treated.
A problem this legible ought to be a problem already being solved, and the reason it is not lies in a misreading of what the problem actually is. The reflex is to treat falling uptake as a failure of communication or of scientific literacy — a deficit of information to be met with a clearer message. The evidence does not support that. As far back as 2019, before the pandemic, Canadians overwhelmingly understood that vaccines work; more than nine in ten believed they were effective at protecting the community.7 The knowledge was already there. The shortfall lies elsewhere — in a set of distinct root causes that no single message addresses, and one of which is the misreading itself.
It helps to name them as a set before taking them in turn. Three are substantive drivers of why uptake fell and why the system struggles to respond: a hardened partisan sorting of vaccination into identity; a continental ideological weather system that imports pressure across the border faster than the response coordinates within it; and a data-visibility collapse that leaves the system unable to see, in much of the country, where protection has thinned. The fourth is not a driver of the disease but of the failed treatment: the persistent mis-classification of a complex challenge as a merely complicated one — the belief that the answer is simply to communicate harder, when the real work is coordination among actors no one controls.
Take the substantive drivers first, beginning with the one that changed most. What shifted is not what people know but whom they trust, and how a health decision came to mark out who they are.
Trust did not so much collapse as relocate.
The deeper driver is grievance. The prevailing read of the public mood in 2025–26 describes a population convinced the system is rigged and that leadership, in government and business alike, is indifferent to ordinary people.8 That conviction does not stay in the economy; it bleeds into health, where it hears any official recommendation as the voice of an establishment that has not earned the benefit of the doubt. The pandemic then turned a private choice into a public allegiance. Vaccine passports and employment mandates made vaccination a political ultimatum: strong support for proof-of-vaccination measures fell from 66 percent to 43 percent in the span of months around the Omicron wave, opposition hardened, and by early 2022 roughly a third of Canadians said the Freedom Convoy reflected genuine public anger rather than a fringe.9 A decision framed as a loyalty test produces a resistance that evidence does not dislodge, because the evidence was never what the resistance was about.
Trust did not vanish in this; it relocated. Canadians increasingly trust what is near to them — their own clinician, their own pharmacist, their employer, their community — and discount what arrives through government podiums or national media, whose credibility on health reporting has slipped into distrust territory.10 The most believable messenger is now the most local one, and the bodies that design campaigns and control supply are the least local actors in the system. A response routed through a central authority is pushing on the lever the public has stopped answering to.
This is why the same recommendation is refused at such different rates, and why the split runs along political identity rather than education or access. The politicization is not a pandemic invention: already in 2019, the argument that vaccination should be a parental choice was twice as common in the Conservative sphere as in the Liberal or NDP spheres.7 The mandates of the COVID years deepened a fault line that predated them. The gradient is now stark — refusal runs near 39 percent among Conservative supporters against 12 to 14 percent elsewhere — and it tracks generalized social trust more than any fact about the vaccines: Alberta, over a decade the least trusting province toward government and institutions, records the country’s highest refusal rate at roughly 35 percent, while higher-trust Quebec sits near 19 percent.5,11 The observation is analytic, not partisan. Vaccination has been sorted into identity, and that sorting is reached only through the messengers each community already trusts — which is, once again, a question of who is coordinated with whom.
Vaccination has been sorted into identity, and a sorted behaviour is not un-sorted by a better pamphlet.
The second driver compounds the first from outside. The partisan sorting does not form in a vacuum; it is fed by a continental ideological weather system, the cross-border cascade of policy reversals and organized opposition traced in Exhibit 6. The networks that carry it coordinate across the Canada–United States line more fluently than the public-health response coordinates within either country — so the pressure arrives faster than the system that must answer it can assemble.
The third driver is quieter but no less disabling: the system often cannot see where it is losing. As Exhibit 5 showed, ten of thirteen jurisdictions cannot publish comparable coverage for their own children, which means catch-up effort cannot be aimed where protection has thinned most. A response cannot be coordinated around a gap it cannot locate.
Three drivers, then — a sorted public, a continental headwind, and a blind spot — none of which a clearer leaflet reaches. Which exposes the fourth and most consequential misreading of all: that this is a complicated problem, solvable by pushing harder on a single, well-understood lever, when it is in fact a complex one, solvable only by coordinating levers that sit in different hands. A complicated problem yields to expertise applied with force. A complex one yields only to the right actors deciding together. Mistake the second for the first and every tool you reach for will be the wrong size — which is exactly the pattern the response has followed.
Everything Tried So Far Pushes a Single Lever.
The response to all of this has not been absent. It has been steady, well funded, and almost entirely single-lever. The dominant instinct is the information deficit: publish more safety data, commission another report, mount another awareness campaign on the theory that the public will comply once it has read enough. It does not work, because the shortfall was never information — and it leaves the people who actually hold the trusted relationship unsupported, with only about 40 percent of front-line clinicians confident they can address a hesitant patient in the time they have.15
The campaigns that do run tend to amplify rather than convene. Canada already has capable messaging coalitions; what they produce is reach — a message in market — not a binding agreement among the actors who control supply, funding, and delivery. Meanwhile the opposing networks are organized, funded, and coordinated across the Canada–United States border more effectively than the pro-science village is coordinated within Canada.14 A campaign built for the open public square is outmatched by an opposition built for the feed.
A broadcast built for the public sphere loses to an adversary built for the algorithmic one.
The other familiar moves fail for reasons easy to name. A manufacturer that funds a trust campaign for its own product is discounted as self-interested, and anticipated as such. A mandate imposed from above reactivates the very grievance that drove refusal in the first place. A federal podium cannot reach a public that now trusts only what is local. And the high-level task force, the standard answer to a complex health problem, produces an authoritative report it has no power to make thirteen provinces fund or deliver — alignment reached politely at the top that never hardens into action below.
What every one of these shares is the shape of its failure. Each pushes one centralized lever, alone, and none puts the trusted front-line messenger in the same room as the actors who control supply, funding, and policy. The diagnosis points straight at the remedy: because trust now lives locally, the only response that can move uptake is one built around local messengers and coordinated across the levers at once. That is not a communications task. It is a coordination task — and it is the half of the problem that remains genuinely unsolved.
One Coordination Problem, and the Village It Spans
The challenge looks different depending on where in the system one stands — but the structure is the same from every seat. Consider it first from the three vantage points where the gap is widest. A manufacturer controls supply but not demand. A public-health agency controls guidance but not delivery. A front-line system controls the trusted relationship but not the strategy or the funding. Each holds one decisive lever and depends on others it cannot direct. That is not a flaw in any of them; it is the architecture of the problem.
Those three are the clearest illustration, not the full cast. Widen the frame and the same one-lever logic runs through every actor whose coordinated move the result depends on — eight in all, each holding a single point of control and none holding the chain.
Naming the eight is the easy part. The harder truth is what each absence costs: leave any one of them out of the room and a specific part of the plan goes undecided or undeliverable. The table below sets out who must be present and what their absence stalls.
The village that must be in the room
| Who needs to be in the room | Role in the problem | Why their absence stalls the solution |
|---|---|---|
| Vaccine Manufacturer | Holds supply, forecasting, product timing, and the resources to underwrite the readiness of the actors the public trusts. | Without a supply-and-forecast commitment tied to the plan, provinces cannot procure with confidence and the season’s delivery is built on a moving target. |
| Public-Health Agency and Advisory Body | Hold national surveillance, scientific guidance, and the message — the evidence base every other actor relies on. | Absent the agency, the room has no shared evidentiary anchor, and thirteen systems risk acting on thirteen different readings of the same data. |
| Provincial and Territorial Immunization Programs | Control funding, procurement, and whether a vaccine is free at the point of care — the decision that most directly shapes demand. | If the actors who hold the funding lever are not present, the cost barrier stays in place and uptake fragments jurisdiction by jurisdiction. |
| Pharmacist Associations | Represent the most accessible immunizers and a highly trusted point of contact, authorized to deliver since 2012. | A season designed without pharmacists omits both the largest delivery channel and one of the few messengers a hesitant patient already believes. |
| Primary Care and Family Physicians | Hold the trusted clinical relationship where most vaccine decisions are actually made or unmade. | Without the clinical voice co-designing the approach, the recommendation that moves patients is left to chance rather than built into the plan. |
| Hospitals and Regional Health Authorities | Deliver immunization, absorb the consequences of low coverage, and manage seasonal surge. | The actors who carry the downstream cost are left to react to a demand failure they had no hand in shaping, and surge planning stays disconnected from prevention. |
| Community, Faith, and Indigenous Health Leaders | Hold trusted reach into the populations where coverage has fallen furthest. | Outreach designed without these leaders is tested on the very communities it most needs to reach only after it has already been built — too late to shape it. |
Six dimensions that must be solved together
Knowing who must be in the room is only half of the brief. The other half is what they have come to resolve. The same coordination failure expresses itself as six distinct dimensions, each of which looks tractable in isolation and none of which any single actor can settle alone.
| Dimension | Why it cannot be solved alone |
|---|---|
| Regulatory Timing | Approvals for updated and combination products run on the regulator’s calendar, not the manufacturer’s or the province’s. A season’s plan depends on a date no single party in the room controls, so procurement, delivery, and messaging must all be sequenced around a milestone owned elsewhere.16 |
| Provincial Funding and Procurement | Whether a vaccine is free at the point of care is decided program-by-program across thirteen jurisdictions. Even with supply secured and evidence agreed, demand fragments wherever a patient faces an out-of-pocket cost, and no national actor can set the funding decision for the provinces. |
| Public Demand and Hesitancy | Uptake is a behaviour held by the public, shaped by identity and information environment more than by data alone. The actor most able to fund a campaign is the least able to change a mind; the change happens in a trusted relationship the funder does not own.5 |
| Trusted-Messenger Activation | The most credible voices — family physicians, pharmacists, community and faith leaders — carry the relationship capital that moves a hesitant patient, but they are not employed by, or formally coordinated with, the bodies that write immunization strategy. Activating them requires the strategists and the messengers to plan together.17 |
| Information Environment and Platform Reputation | The narrative about a vaccine — and about the platform it is built on — is contested on social media and amplified across the border by organized networks. No manufacturer, agency, or clinician controls that environment; countering it requires coordinated, consistent signal from many trusted sources at once.14 |
| Delivery Bandwidth and Equity of Access | The physical work of immunizing falls to pharmacies, primary care, and public-health clinics, whose capacity is finite and whose reach into rural, remote, newcomer, and Indigenous communities is uneven. Closing the gap where it is widest requires delivery partners and community leaders to design access together, not to receive a plan built without them. |
What the Moment Calls For
Each of the familiar instruments is built for a specific job, does it well, and then hands the work onward. A public-awareness campaign sharpens a message, which matters when the public has not heard the case — though here the case is widely known and the obstacle is trust in who is making it. An expert advisory body produces sound recommendations, which carry a strategy forward until the moment named owners and resolved trade-offs are required. A stakeholder summit builds relationships and surfaces perspectives, invaluable early on, before the question becomes which province funds a program, who counsels the hesitant patient, and in what order the moves are made.
Four formats, and the job each is built for
| Decision-Forcing Session | Public-Awareness Campaign | Expert Advisory Body | Stakeholder Summit | |
|---|---|---|---|---|
| Primary purpose | Convert alignment that already exists into a jointly owned plan while the window is still open. | Sharpen and broadcast a message to a public that has not yet heard the case. | Produce sound, evidence-based recommendations on what should be done. | Build relationships and surface perspectives across stakeholders. |
| Who is in the room | The people who hold the actual levers — funders, regulators, deliverers, and trusted messengers — together. | A communications team and its agency; the public is the audience, not a participant. | Subject-matter experts and scientific advisers. | Senior leaders and stakeholders, often standing in for the implementers. |
| What it produces | A 30/60/90-day plan with named owners and the trade-offs already resolved. | Awareness and reach — a message in market. | A report or set of recommendations. | Shared understanding and a record of perspectives. |
| Are trade-offs forced? | Yes — competing options are tested against each other and against the people who must deliver them. | No — the trade-offs sit upstream of the message. | Partly — within the evidence, but not across who funds, leads, or delivers. | Rarely — options are described rather than chosen between. |
| Endorsement and ownership | A recommendation every party in the room endorses — pre-sold to the organizations represented, so execution is markedly faster and easier. | None — the audience receives the message, it does not commit to act. | Authoritative, but not owned by the implementers who would have to carry it out. | General agreement that tends to stay at the altitude it was reached. |
| Best used when | A few hard problems keep returning to the agenda and progress now depends on a committed, jointly owned plan. | The public has not yet heard the case and the task is simply to be heard. | A strategy needs an authoritative evidence base before owners and trade-offs are in play. | Early on — when relationships and shared understanding still need to be built. |
Each of these tools is good at what it is for, and the trust problem has simply travelled to the stage that comes after. It is no longer short of analysis or of goodwill; what it asks for now is a mechanism that converts shared understanding into a binding, jointly owned decision while a season is still open. That mechanism has a recognizable shape, built around three deliberate stages, and it is used sparingly — only where a problem genuinely warrants the cost of getting the right people in one room and holding them to a decision. A trust gap that is really a coordination gap is exactly such a problem.
The distinguishing feature of a decision-forcing process is that it treats the room itself as the instrument. Attendance is restricted to the people who hold the relevant levers; the agenda is built around the trade-offs that have been deferred rather than the topics that are comfortable; and the session is judged not by the quality of the discussion but by whether a committed decision exists at the end. Those are demanding conditions, which is why the format is reserved for the few challenges that have outgrown what discussion alone can give them.
Analyze → Diverge → Converge
The structure is simple to state and demanding to run: Analyze, then Diverge, then Converge. Its discipline lies in keeping the stages separate — surfacing the real constraints before generating options, and generating options before forcing a choice — and in insisting that the people who control the constraints are physically in the room. Applied directly to the challenge that touches all three vantage points at once — making sure a season’s vaccines actually reach arms — it runs as follows.
Analyze: Putting the Real Picture in Front of the Real Owners
Begin with what the Analyze stage would put on the table. The coverage figure sits below the control threshold; the trust figure shows a public that still believes its clinicians but has grown readier to decline; and the calendar fixes a date, because a respiratory season does not wait for alignment.4,5 None of these is in dispute. The work of the stage is not to re-establish the facts but to use them to expose how thoroughly the response is split across owners who each see only part of it.
As Exhibit 5 shows, in much of the country that picture does not exist in comparable form.
Diverge: Generating Options That Cross the Boundaries
The Diverge stage then generates options that no single actor, left to itself, would reach — because the options that matter cut across the boundaries the participants arrived with. Designing a season around the trusted messenger rather than the broadcast campaign is one move: equipping pharmacists and family physicians with the time, the tools, and the funding to have the conversation, instead of asking a manufacturer or an agency to have it on their behalf. Aligning provincial funding so that the patient faces no cost barrier is a second. A manufacturer standing behind the village — underwriting the readiness of the actors the public actually trusts, rather than fronting the message itself — is a third. The value of separating this stage is that it suspends, briefly, the instinct to defend existing roles long enough for combinations like these to appear.
Converge: Decisions Built to Survive the Season
The Converge stage is where the process earns its keep. It produces not a recommendation but a decision: a 30/60/90-day plan in which a named provincial program commits to a funding decision by a date, a named pharmacist association commits to a counselling-and-delivery protocol, a named public-health lead commits to a trusted-messenger activation in the communities where coverage is lowest, and the manufacturer commits supply and forecasting against that plan. The deliverable is a record of who will do what, by when, with the trade-offs — who pays, who leads the message, who reaches which community — already resolved in the room rather than carried forward to a future meeting.
Because uptake is measurable and the season is dated, each commitment can be attached to a baseline and a deadline. A funding decision can be tested against whether the cost barrier actually fell; an activation can be measured against coverage in the specific communities it targeted. A decision that can be measured is a decision that can be defended — and, the following year, improved. That is the difference between a plan that survives the season and a consensus that dissolves once everyone has left the room. Every one of the eight actors mapped earlier has a named commitment in that plan; none is a spectator, because none was a spectator in the problem.
Convening, and the Process That Sits Naturally Beside It
There is a clear test for when that moment has arrived, and any organization can run it on itself. Look across several years of the calendar and ask one question: are the same issues being explored, in much the same terms, year after year? Where complex challenges are steadily being resolved and moved off the list, the existing tools are doing their job and there is no reason to reach for another. Where a few hard problems — coverage gaps, the trusted-messenger disconnect, the funding decision that never quite gets made before the season — keep returning to successive agendas, that recurrence is itself the signal: the challenge has travelled past the point where more discussion adds much, into territory where progress depends on a different kind of process, one built to bring the implementers into the room, test real options against real constraints, and force a committed decision. The choice is not between convening and something that replaces it. It is whether to set, alongside the convening that health systems already do so well, the occasional session whose purpose is to convert alignment into committed action while the window is still open. With the next respiratory season functioning as a deadline, the value of that second kind of session is at its highest precisely now.
The Question Before the Season Opens
The erosion of trust in science and vaccines is real, and part of it is genuinely hard: a politically sorted reluctance that no campaign, study, or workshop will argue away. That part is not the claim of this paper. The narrower and more tractable point is that the system’s response to it is failing for a different reason — not for want of knowledge or goodwill, but for want of coordination. The responses are known, the data is in hand, and the people who would need to act are, for the most part, willing. What remains is the setting that brings those willing parties — and the local messengers the public still trusts — to a shared decision before the moment passes. No single actor — not the manufacturer, not the agency, not the front-line system — could produce that result alone, and none can substitute for it. That is not a verdict on any of them; it is the structure of the problem. The question a season’s deadline poses is the practical one: in the time still available, will the alignment that already exists be converted into a plan that named people have committed to own — turning, as the best work in health systems eventually must, an excellent conversation into a decision.
The analysis is done and the goodwill is real. The remaining work is coordination, and it has a known shape and a known instrument.
Start a Conversation
If this is the shape of the challenge — a trust gap that is really a coordination gap, with a season as its deadline — the next step is a structured process. A Mind Meeting convenes the internal team alongside the full village that governs the constraints: the manufacturer, the public-health and advisory bodies, the provincial programs, the pharmacists and physicians, the hospitals, and the community, faith, and Indigenous health leaders whose coordinated action the result depends on. It surfaces each constraint, forces the trade-offs, and produces a 30/60/90-day plan with named owners. The analysis is done and the goodwill is real. The remaining work is coordination, and it has a known shape and a known instrument.
Mark McCarvill is the founder of Mind Meeting Group, a Vancouver-based strategy and facilitation firm. He has led more than 100 strategic workshops, aligned more than 3,000 leaders and stakeholders, and worked on challenges touching more than $350 billion in portfolio value, including engagements with seven of the global top-twelve pharmaceutical companies. Mind Meeting Group specializes in complex, multi-stakeholder challenges where the answer is knowable but not yet executable — and where the right process, not more analysis, is what converts strategy into committed action.
In the health-system domain, MMG has convened multi-stakeholder workshops on diagnostic and therapeutic access in Canada — including a cross-sector strategy for MRI access for early-Alzheimer’s patients that produced 19 prioritized recommendations, and a national care-pathway workshop that aligned clinicians, advocates, home-care providers, and provincial policy actors around 18 consensus recommendations — working with clinicians, pharmacists, payers, patient advocates, and policy experts to turn rigorous analysis into coalition-ready, executable plans.
- Canada co-hosts the FIFA World Cup 2026 (June 11–July 19, 2026), with matches in Toronto (BMO Field) and Vancouver (BC Place): FIFA; Government of Canada, 2026.
- Canada’s loss of measles elimination status: Public Health Agency of Canada, “Statement on Canada’s Measles Elimination Status,” November 2025.
- Case counts (147 in 2024; more than 5,000 in 2025) and the outbreak originating in late 2024: PHAC, Canadian Measles and Rubella Surveillance System / Measles and Rubella Weekly Monitoring Report, 2025.
- Two-dose MMR coverage at age seven falling from 85.4% to 74.9% (2019–2023), against the ~95% threshold for measles control, and published only as a national blend across reporting jurisdictions: A. Jeevakanthan et al., “Routine vaccination coverage at ages 2 and 7, before, during, and after the COVID-19 pandemic: Results from the STARVAX surveillance system,” Canadian Journal of Public Health (2025, corrected).
- Roughly one-quarter of Canadians declining a physician-recommended vaccine (24%), continued high trust in family doctors, and the partisan gradient (about 39% of Conservative supporters versus 12–14% of others): Angus Reid Institute survey, May 2026 (reported in Canadian press).
- Hospitalizations for vaccine-preventable respiratory diseases more than doubling in 2024–25 (142 per 100,000), with COVID-19 accounting for over 40% (25,501) at an average $28,500 and 23 days per patient: Canadian Institute for Health Information, “Hospitalizations for vaccine-preventable respiratory diseases surpass pre-pandemic levels,” April 16, 2026.
- Strong pre-pandemic belief in vaccine effectiveness (more than nine in ten Canadians in 2019) and the “parental choice” argument running roughly twice as high in the Conservative sphere as in the Liberal or NDP spheres: Angus Reid Institute vaccine-confidence tracking, 2019.
- The “Crisis of Grievance” — a public mood defined by the belief that the system is rigged and that government and corporate leadership are indifferent to ordinary people, bleeding from economic into health perceptions: Edelman Trust Barometer, 2025–26.
- Collapse in strong support for proof-of-vaccination measures (66.0% to 43.1%) around the Omicron wave, hardening opposition, and the public split on the Freedom Convoy (roughly one-third viewing it as genuine public anger): peer-reviewed study of Canadian attitudes toward COVID-19 vaccine mandates, 2022 (PMC).
- The relocation of trust toward local and personal sources (own clinician, pharmacist, employer, community) over central government and national media, and the decline of trust in media health reporting into distrust territory (~39%): Edelman Trust Barometer and Canadian trust-in-science synthesis, 2024–26.
- Provincial variation in refusal — Alberta highest at roughly 35% (the least trusting province over a decade of polling) and Quebec lowest near 19% (correlating with higher generalized social trust): CanTrust Index / Leger Healthcare, 2025–26.
- U.S. federal actions — replacement of the membership of the CDC’s Advisory Committee on Immunization Practices (June 2025); cancellation of roughly US$500 million in mRNA vaccine research (August 2025); removal of COVID-19 vaccines from the routine schedule for healthy children and pregnant people (May 2025): U.S. Department of Health and Human Services; reporting by NPR and STAT, 2025.
- FDA narrowing of COVID-19 vaccine eligibility by age and risk status (2025), and the objection of twelve former FDA commissioners (December 2025): NPR; BioPharma Dive, 2025.
- Organized anti-vaccine networks operating across the Canada–U.S. border (e.g., Vaccine Choice Canada and affiliated groups): Canadian public-interest reporting (CBC), 2024–25.
- Limits of the information-deficit approach and of messaging-only coalitions (e.g., ScienceUpFirst, 19 To Zero) that amplify a message without convening binding cross-actor delivery, and the roughly 40% of front-line clinicians confident in addressing hesitancy: Leger Healthcare provider survey and Canadian program reviews, 2025–26.
- Seasonal respiratory franchise strategy and a flu/COVID combination under review in Canada: Moderna business and pipeline update, 44th Annual J.P. Morgan Healthcare Conference, January 2026.
- Pharmacist authority to immunize in Canada since 2012 and the positive effect of pharmacist-led immunization on uptake: systematic review and meta-analysis of pharmacist interventions on immunization uptake (peer-reviewed), 2024.
- Roughly 87–90% of those infected during the 2024–26 outbreak were unvaccinated, and approximately 84% of 2025 cases were in Ontario and Alberta: PHAC, Measles and Rubella Weekly Monitoring Report, 2025; provincial health ministries.
- Infant deaths during the outbreak (including congenital measles) and the disproportionate burden on newborns and pregnant patients, reported in aggregate: CMAJ; CBC News and CIDRAP reporting, 2025. Figures are presented in aggregate to protect the privacy of affected families.